Morquio Syndrome: Symptoms, Diagnosis, and Treatment

What Is Morquio Syndrome?

Morquio syndrome, also known as mucopolysaccharidosis type IV (MPS IV), is a rare inherited metabolic disorder that primarily affects how the body builds and maintains bones and cartilage. It belongs to a larger group of conditions called lysosomal storage diseases, where the body cannot properly break down certain complex sugar molecules. In Morquio syndrome, these molecules accumulate in cells, especially in connective tissues, leading to progressive skeletal abnormalities and other systemic complications.

Children with Morquio syndrome are usually born looking healthy, with no obvious signs of the condition. Symptoms typically begin to appear between the ages of 1 and 3 years, as growth and development reveal characteristic changes in the skeleton. The condition is lifelong and progressive, meaning it tends to worsen over time, but intelligence is generally unaffected, especially in the more common form, MPS IVA.

How Morquio Syndrome Develops

At the cellular level, Morquio syndrome results from a deficiency in specific enzymes needed to break down long chains of sugar molecules called glycosaminoglycans (GAGs), particularly keratan sulfate. Normally, these GAGs are broken down in cellular compartments called lysosomes. When the required enzyme is missing or not working properly, keratan sulfate builds up inside cells, disrupting normal tissue function.

This accumulation interferes with the development of cartilage and bone, especially in the spine, ribs, long bones, and joints. Over time, this leads to a distinctive pattern of skeletal dysplasia, including short stature, spinal deformities, and joint instability. The severity and rate of progression can vary significantly between individuals, even within the same family.

Types of Morquio Syndrome

Morquio syndrome is divided into two main types, based on the specific enzyme deficiency and the gene involved:

• MPS IVA (Morquio A): Caused by a deficiency of the enzyme N-acetylgalactosamine-6-sulfatase, due to mutations in the GALNS gene. This is the more common and typically more severe form.
• MPS IVB (Morquio B): Caused by a deficiency of the enzyme beta-galactosidase, due to mutations in the GLB1 gene. This form is rarer and often has a milder, slower progression.

Both types are inherited in an autosomal recessive pattern, meaning a child must inherit two faulty copies of the gene—one from each parent—to develop the condition. Parents who are carriers usually show no symptoms themselves.

Recognizing the Signs and Symptoms

Because Morquio syndrome affects multiple body systems, its signs can be quite varied. Early recognition is important for timely evaluation and management. Common features include:

Skeletal and Growth Changes

• Short stature, particularly with a short trunk (short torso)
• Progressive spinal abnormalities such as kyphosis (forward rounding of the upper back), scoliosis (sideways curvature), and platyspondyly (flattened vertebrae)
• Shortened neck and instability at the base of the skull (odontoid hypoplasia), which can put pressure on the spinal cord
• Bell-shaped or protruding chest (pectus carinatum)
• Knock-knees (genu valgum) and other leg alignment issues
• Joint hypermobility or stiffness, often leading to an abnormal gait and frequent falls
• Hip dysplasia, subluxation, or dislocation, which can cause pain and limit walking

Facial and Dental Features

• Coarse or prominent facial features, especially in the lower face
• Widely spaced teeth with thin enamel and increased risk of cavities
• Abnormal tooth shape, such as pointed cusps on back teeth and pitting on the outer surfaces

Other Systemic Involvements

• Clouding of the cornea, which can affect vision
• Hearing loss, often conductive or mixed type
• Enlarged liver (hepatomegaly), though usually not causing liver dysfunction
• Heart valve abnormalities and other cardiovascular issues
• Respiratory problems due to chest wall deformities and spinal cord compression

Neurological complications can arise if the upper spine becomes unstable and compresses the spinal cord, potentially leading to weakness, numbness, or loss of coordination in the legs. Regular monitoring by a neurologist or spine specialist is often necessary.

When to Seek Medical Evaluation

Parents or caregivers should consider a medical evaluation if a child shows:

• Noticeable slowing of growth, especially in height, after age 1–2 years
• Increasing difficulty with walking, frequent falls, or an unusual gait
• Visible changes in posture, such as a rounded back or prominent chest
• Joint pain, stiffness, or hip discomfort, particularly in older children
• Development of knock-knees or other leg deformities
• Recurrent ear infections or hearing concerns
• Cloudy eyes or vision changes

Because Morquio syndrome is rare, it may not be the first condition considered. A pediatrician, geneticist, or orthopedic specialist can help determine whether further testing is needed.

How Diagnosis Is Made

Diagnosing Morquio syndrome involves a combination of clinical evaluation, imaging, and laboratory testing:

Initial Clinical Assessment

A doctor will review the child’s medical history, growth pattern, and family history. A physical exam will focus on skeletal features, joint mobility, facial characteristics, and any signs of organ involvement.

Imaging Studies

• X-rays: Can show characteristic changes in the spine (platyspondyly, odontoid hypoplasia), hips (dysplasia, subluxation), and long bones.
• MRI of the cervical spine: Often performed to assess spinal cord compression and stability at the skull–spine junction.
• CT scans: May be used in some cases to get detailed views of bone structure.

Specialized Laboratory Tests

• Urine GAG analysis: Measures levels of glycosaminoglycans; elevated keratan sulfate is a hallmark of MPS IV.
• Enzyme assays: Blood or skin fibroblast tests to measure the activity of N-acetylgalactosamine-6-sulfatase (for MPS IVA) or beta-galactosidase (for MPS IVB).
• Genetic testing: DNA analysis to identify mutations in the GALNS or GLB1 genes, confirming the diagnosis and type.

Differential Diagnosis

Other conditions that may resemble Morquio syndrome include other mucopolysaccharidoses (like MPS I or MPS VI), other skeletal dysplasias (such as spondyloepiphyseal dysplasia), and some forms of osteogenesis imperfecta. A multidisciplinary team is often involved to distinguish between these possibilities.

Current Treatment and Management Approaches

There is currently no cure for Morquio syndrome, but a range of treatments can help manage symptoms, prevent complications, and improve quality of life. Care is typically coordinated by a team of specialists, including geneticists, orthopedic surgeons, neurologists, cardiologists, pulmonologists, audiologists, ophthalmologists, dentists, and physical therapists.

Enzyme Replacement Therapy (ERT)

For MPS IVA, an enzyme replacement therapy (ERT) called elosulfase alfa (Vimizim®) is available. This treatment involves regular intravenous infusions of the missing enzyme, aiming to reduce GAG accumulation and slow disease progression. ERT does not reverse existing skeletal damage but may help stabilize some aspects of the disease, such as endurance and respiratory function.

Orthopedic and Surgical Interventions

• Cervical spine fusion: Often recommended if there is significant instability or spinal cord compression at the base of the skull, to prevent neurological injury.
• Spinal fusion for scoliosis/kyphosis: May be performed to correct severe spinal curvatures and improve posture and breathing.
• Hip reconstruction or total hip replacement: Can relieve pain and improve mobility in children and adults with severe hip dysplasia or arthritis.
• Lower limb osteotomies: Surgical realignment of the legs to correct knock-knees or other deformities.

Respiratory and Cardiac Support

• Regular pulmonary function tests and sleep studies to monitor for obstructive or restrictive lung disease.
• Use of CPAP or other respiratory support if needed.
• Periodic echocardiograms and cardiology follow-up to detect and manage heart valve problems.

Rehabilitation and Physical Care

• Physical therapy to maintain joint mobility, strengthen muscles, and improve balance and gait.
• Occupational therapy to support daily living skills and adaptive equipment use.
• Use of braces, walkers, or wheelchairs as mobility declines, to maintain independence and safety.

Dental and Sensory Care

• Regular dental visits with a dentist experienced in special needs care, focusing on enamel protection and cavity prevention.
• Hearing evaluations and hearing aids if hearing loss is present.
• Regular eye exams to monitor corneal clouding and other vision issues.

Supporting a Child with Morquio Syndrome

Living with Morquio syndrome presents unique challenges, but with the right support, children can lead active, meaningful lives. Families play a central role in managing care, advocating for services, and fostering emotional well-being.

Building a Care Team

Work with your child’s primary care provider to assemble a multidisciplinary team tailored to your child’s needs. Regular follow-up appointments and clear communication among specialists are key to coordinated care.

Education and School Planning

• Since cognitive development is usually normal, most children can attend mainstream schools with appropriate accommodations.
• Develop an Individualized Education Program (IEP) or 504 plan to address physical access, mobility, fatigue, and any learning support needs.
• Ensure the school environment is accessible, with ramps, elevators, and adaptive seating as needed.

Emotional and Social Well-Being

• Encourage participation in age-appropriate activities, hobbies, and social events.
• Consider counseling or support groups for both the child and family members to address emotional challenges.
• Promote self-advocacy skills as the child grows older, helping them understand their condition and communicate their needs.

Practical Daily Living Tips

• Use adaptive clothing, shoes, and assistive devices to make dressing and mobility easier.
• Modify the home environment (e.g., grab bars, shower chairs, accessible bathrooms) to support independence.
• Plan activities with rest breaks and avoid overexertion, especially in hot weather or high altitudes.

Prognosis and Long-Term Outlook

The long-term outlook for Morquio syndrome varies widely depending on the type, severity, and access to care. In general:

• Children with MPS IVA often experience significant skeletal and respiratory challenges, and many become wheelchair-dependent in adolescence or early adulthood.
• Life expectancy can be reduced, particularly if there are severe spinal cord compression, respiratory failure, or heart complications. With modern management, many individuals live into adulthood, though some may not survive beyond their twenties or thirties in more severe cases.
• Those with MPS IVB often have a milder course and may live longer, with fewer severe complications.

Early diagnosis, proactive monitoring, and timely interventions can significantly improve outcomes and quality of life. Ongoing research into new therapies, including gene therapy and improved ERT, offers hope for future advances.

Frequently Asked Questions

Is Morquio syndrome inherited?

Yes, Morquio syndrome is inherited in an autosomal recessive pattern. This means both parents must carry a copy of the faulty gene for a child to be affected. Each child of two carrier parents has a 25% chance of having the condition.

Does Morquio syndrome affect intelligence?

In MPS IVA (Morquio A), intelligence is typically normal. In MPS IVB (Morquio B), some individuals may experience mild to moderate intellectual disability, but this is not universal. Cognitive development should be monitored as part of routine care.

Can Morquio syndrome be detected before birth?

Yes, prenatal testing is possible if the family has a known genetic mutation. Chorionic villus sampling (CVS) or amniocentesis can be used to test for the condition in at-risk pregnancies. Preimplantation genetic testing (PGT) is also an option for some families undergoing in vitro fertilization.

What is the role of enzyme replacement therapy?

Enzyme replacement therapy (ERT) for MPS IVA helps reduce the buildup of glycosaminoglycans in the body. It does not reverse existing bone damage but may slow disease progression, improve endurance, and support respiratory function. ERT is given as regular IV infusions and is part of a broader treatment plan.

How can families find support and resources?

Families can connect with patient advocacy organizations, rare disease networks, and support groups. These groups provide information, emotional support, and opportunities to connect with other families facing similar challenges. Your child’s care team can often help identify local and national resources.